Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2016

Open Access 01-12-2016 | Research article

Traditional Chinese medicine, Danlou tablets alleviate adverse left ventricular remodeling after myocardial infarction: results of a double-blind, randomized, placebo-controlled, pilot study

Authors: Shuai Mao, Lei Wang, Wenwei Ouyang, Yuanshen Zhou, Jianyong Qi, Liheng Guo, Minzhou Zhang, Aleksander Hinek

Published in: BMC Complementary Medicine and Therapies | Issue 1/2016

Login to get access

Abstract

Background

Danlou tablets, a patented Chinese Medicine, have been long approved for the treatment of ischemic heart disease in China. While numerous empirical observations suggested Danlou tablets could decrease frequency and duration of angina pectoris attacks, evidence supporting its efficacy on cardiac remodeling remains inadequate. Therefore, this pilot trial was designed to determine whether Danlou tablets would reduce adverse left ventricular (LV) remodeling in patients with myocardial infarction (MI).

Methods and Results

Eligible patients with acute MI were enrolled and randomly assigned to Danlou tablets or placebo groups, superimposed on standard treatment for MI. Then, in addition to assessment of the clinical outcome, the changes in LV volumes were evaluated by a serial echocardiography. In total, 83 patients (Danlou tablets 42 and placebo 41) completed 90 days of treatment and had complete baseline and outcome data. Standard echocardiographic evaluations revealed significant differences in the change of LV end-diastolic volume index (LVEDVi) between group of patients treated with Danlou tablets and the placebo group (−4.49 ± 7.29 vs. −0.34 ± 9.01 mL/m2, P < 0.001). The reduction in LVEDVi was independent of beta-blocker, ACE inhibitors/ARBs use. Furthermore, treatment with Danlou tablets significantly reduced LV end-systolic volume index (−4.09 ± 5.85 vs. −0.54 ± 5.72 mL/m2, P < 0.001) and improved the LV ejection fraction (4.83 ± 9.23 vs. 0.23 ± 8.15 %, P < 0.001), as compared to placebo. Meaningfully, the incidence of the major adverse cardiovascular events was also lower in patients receiving Danlou tablets (P < 0.05).

Conclusion

Superimposed on the standard pharmacologic treatment, Danlou tablets significantly reversed post-MI adverse LV remodeling, thereby contributed to the overall positive clinical outcome.

Trial registration

clinicaltrials.gov identifier NCT02675322 (February 1, 2016).
Appendix
Available only for authorised users
Literature
1.
Daubert MA, Massaro J, Liao L, Pershad A, Mulukutla S, Magnus Ohman E, Popma J, O’Neill WW, Douglas PS. High-risk percutaneous coronary intervention is associated with reverse left ventricular remodeling and improved outcomes in patients with coronary artery disease and reduced ejection fraction. Am Heart J. 2015;170(3):550–8.CrossRefPubMed
2.
Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. On Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35:569–82.CrossRefPubMed
3.
St John Sutton M, Lee D, Rouleau JL, Goldman S, Plappert T, Braunwald E, Pfeffer MA. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation. 2003;107:2577–82.CrossRefPubMed
4.
Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112:3738–44.CrossRefPubMed
5.
Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med. 2006;166:659–66.CrossRefPubMed
6.
Doughty RN, Whalley GA, Walsh HA, Gamble GD, López-Sendón J, Sharpe N. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation. 2004;109:201–6.CrossRefPubMed
7.
St John Sutton M, Ghio S, Plappert T, Tavazzi L, Scelsi L, Daubert C, Abraham WT, Gold MR, Hassager C, Herre JM, Linde C. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation. 2009;120:1858–65.CrossRefPubMed
8.
Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM, Antoniucci D. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation. 2002;106:2351–7.CrossRefPubMed
9.
Springeling T, Kirschbaum SW, Rossi A, Baks T, Karamermer Y, Schulz C, Ouhlous M, Duncker DJ, Moelker A, Krestin GP, Serruys PW, de Feyter P, van Geuns RJ. Late cardiac remodeling after primary percutaneous coronary intervention-five-year cardiac magnetic resonance imaging follow-up. Circ J. 2012;77:81–8.CrossRefPubMed
10.
Li X, Zhang J, Huang J, Ma A, Yang J, Li W, Wu Z, Yao C, Zhang Y, Yao W, Zhang B, Gao R. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol. 2013;62(12):1065–72.CrossRefPubMed
11.
Wang Y, Liu J, Ma A, Chen Y. Cardioprotective effect of berberine against myocardial ischemia/reperfusion injury via attenuating mitochondrial dysfunction and apoptosis. Int J Clin Exp Med. 2015;8(8):14513–9.PubMedPubMedCentral
12.
Luo J, Song W, Yang G, Xu H, Chen K. Compound Danshen (Salvia miltiorrhiza) dripping pill for coronary heart disease: an overview of systematic reviews. Am J Chin Med. 2015;43(1):25–43.CrossRefPubMed
13.
Wu XL, Zheng B, Jin LS, Zhang RN, He M, Yang Z, Wen JK. Chinese medicine Tongxinluo reduces atherosclerotic lesion by attenuating oxidative stress and inflammation in microvascular endothelial cells. Int J Clin Exp Pathol. 2015;8(6):6323–33.PubMedPubMedCentral
14.
Qi J, Yu J, Wang L, Guo L, Ma S, Huang D, Zhou M, Wu J, Zhang M. Tongguan capsule protects against myocardial ischemia and reperfusion injury in mice. Evid Based Complement Alternat Med. 2013;2013:159237.PubMedPubMedCentral
15.
Gao LN, Zhou X, Zhang Y, Cui YL, Yu CQ, Gao S. The anti-inflammatory activities of ethanol extract from Dan-Lou prescription in vivo and in vitro. BMC Complement Altern Med. 2015;15:317.CrossRefPubMedPubMedCentral
16.
Ji RZ, Yu CH, He ZQ, Wu F, Liang C, Wu Z. Recipe of removing both phlegm and blood stasis inhibits atherosclerosis progression and promotes plaque stability in a rabbit mode. Heart. 2013;99:A83.
17.
Liu JX, Lin CR, Ren JX, Li L, Ren JG, Fu JH, Liu GY. Experimental study on pathogenetic evolvement regularity of phlegm, toxin and blood-stasis syndromes in Chinese miniswine with phlegm-stasis cementation syndrome of coronary heart disease. China J Chin Mater Med. 2013;38(23):4138–43.
18.
Dong J, Zhu Y, Gao X, Chang Y, Wang M, Zhang P. Qualitative and quantitative analysis of the major constituents in Chinese medicinal preparation Dan-Lou tablet by ultra high performance liquid chromatography/ diode-array detector/ quadrupole time-of-flight tandem mass spectrometry. J Pharm Biomed Anal. 2013;80:50–62.CrossRefPubMed
19.
Wang L, Mao S, Qi JY, Ren Y, Guo X, Chen K, Zhang M. Effect of Danlou tablets on peri-procedural myocardial injury among patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndrome: a study protocol of a multicenter, randomized, controlled trial. Chin J Integr Med. 2015;21(9):662–6.CrossRefPubMed
20.
Liem SS, van der Hoeven BL, Oemrawsingh PV, Bax JJ, van der Bom JG, Bosch J, Viergever EP, van Rees C, Padmos I, Sedney MI, van Exel HJ, Verwey HF, Atsma DE, van der Velde ET, Jukema JW, van der Wall EE, Schalij MJ. MISSION!: optimization of acute and chronic care for patients with acute myocardial infarction. Am Heart J. 2007;153:14 e1–1.
21.
Lechat P, Escolano S, Golmard JL, Oemrawsingh PV, Bax JJ, van der Bom JG, Bosch J, Viergever EP, van Rees C, Padmos I, Sedney MI, van Exel HJ, Verwey HF, Atsma DE, van der Velde ET, Jukema JW, van der Wall EE, Schalij MJ. Prognostic value of bisoprolol-induced hemodynamic effects in Heart Failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation. 1997;96:2197–205.CrossRefPubMed
22.
Naqvi TZ, Padmanabhan S, Rafii F, Hyuhn HK, Mirocha J. Comparison of usefulness of left ventricular diastolic versus systolic function n as a predictor of outcome following primary percutaneous coronary angioplasty for acute myocardial infarction. Am J Cardiol. 2006;97:160–6.CrossRefPubMed
23.
Collier P, Watson CJ, Maarten HE, Phelan D, McGorrian C, Tolan M, Ledwidge MT, McDonald KM, Baugh JA. Getting to the heart of cardiac remodelling; how collagen subtypes may contribute to phenotype. J Mol Cell Cardiol. 2012;52:148–53.CrossRefPubMed
24.
Mao S, Li X, Wang L, Yang PC, Zhang M. Rationale and design of sodium tanshinone IIA sulfonate in left ventricular remodeling secondary to acute myocardial infarction (STAMP-REMODELING) trial: a randomized controlled study. Cardiovasc Drugs Ther. 2015;29:535–42.CrossRef
25.
Yang Z, Hong T, Liu YM. Protection of Danlou tablets on hyperlipidemia and vascular endothelial injury in rats. World J Integr Tradit Western Med. 2010;5(6):491–4. Chinese.
26.
Hong M. Effects of Danlou tablets on myocardial infarction size and ventricular remodeling in Rats. Chine J Exp Tradit Med Formulae. 2011;17(10):208–11. Chinese.
27.
Guo LL, Wang J, Lin F, He YX. Effect of Danlou tablets on arrhythmia model rats induced by transient myocardial ischemia/reperfusion. Chin J Integr Tradit Western Med. 2014;34(9):1125–9. Chinese.
28.
Mao S, Wang Y, Zhang M, Hinek A. Phytoestrogen, tanshinone IIA diminishes collagen deposition and stimulates elastogenesis in cultures of human cardiac fibroblasts. Exp Cell Res. 2014;10:62–7.
29.
Mao S, Li W, Qa’aty N, Vincent M, Zhang M, Hinek A. Tanshinone IIA inhibits angiotensin II induced extracellular matrix remodeling in human cardiac fibroblasts - Implications for treatment of pathologic cardiac remodeling. Int J Cardiol. 2016;202:110–7.CrossRefPubMed
30.
Wang SH, Wang J, Li J. Efficacy assessment of treating patients with coronary heart disease angina of phlegm and stasis mutual obstruction syndrome by Danlou tablets. Chin J Integr Tradit Western Med. 2012;32(8):1051–5. Chinese.
31.
Hudson MP, Armstrong PW, Ruzyllo W, Brum J, Cusmano L, Krzeski P, Lyon R, Quinones M, Theroux P, Sydlowski D, Kim HE, Garcia MJ, Jaber WA, Weaver WD. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol. 2006;48(1):15–20.CrossRefPubMed
32.
Hanada K, Higuma T, Nishizaki F, Sukekawa T, Yokota T, Yamada M, Saito S, Kushibiki M, Oikawa K, Abe N, Tomita H, Osanai T, Okumura K. Randomized study on the efficacy and safety of landiolol, an ultra-short-acting beta1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J. 2012;76:439–45.CrossRefPubMed
33.
Ceconi C, Freedman SB, Tardif JC, Hildebrandt P, McDonagh T, Gueret P, Parrinello G, Robertson M, Steg PG, Tendera M, Ford I, Fox K, Ferrari R. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol. 2011;146:408–14.CrossRefPubMed
34.
Moller JE, Hillis GS, Oh JK, Reeder GS, Gersh BJ, Pellikka PA. Wall motion score index and ejection fraction for risk stratification after acute myocardial infarction. Am Heart J. 2006;151:419–25.CrossRefPubMed
Metadata
Title
Traditional Chinese medicine, Danlou tablets alleviate adverse left ventricular remodeling after myocardial infarction: results of a double-blind, randomized, placebo-controlled, pilot study
Authors
Shuai Mao
Lei Wang
Wenwei Ouyang
Yuanshen Zhou
Jianyong Qi
Liheng Guo
Minzhou Zhang
Aleksander Hinek
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2016
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-016-1406-4

Other articles of this Issue 1/2016

BMC Complementary Medicine and Therapies 1/2016 Go to the issue

Research article

Effects of Greenselect Phytosome® on weight maintenance after weight loss in obese women: a randomized placebo-controlled study

Research article

Anti-fatigue effect of Amarkand on endurance exercise capacity in rats

Research article

Rg3-enriched ginseng extract ameliorates scopolamine-induced learning deficits in mice

Research article

Estrogenic and cytotoxic potentials of compounds isolated from Millettia macrophylla Benth (Fabaceae): towards a better understanding of its underlying mechanisms

Research article

Dendropanax morbifera Léveille extract ameliorates cadmium-induced impairment in memory and hippocampal neurogenesis in rats

Research article

Anti-cancer activity of Psoralea fructus through the downregulation of cyclin D1 and CDK4 in human colorectal cancer cells